Nisarg Shah is an Analyst at Catalio Capital Management, LP focusing on public equity investments across healthcare with a specialization in MedTech, Genomics, and Tools and Diagnostics sectors.
Prior to joining Catalio, Nisarg was an Analyst at Moore Capital Management, where he focused on the tools & medtech space. Earlier in his career, he was an Equity Research Analyst covering Life Science Tools & Diagnostics at Barclays, Nephron, and Bank of America.
Nisarg earned his B.S. degree in Finance from the Indiana University Kelley School of Business.